The search for a better Faslodex continues

Last week’s licensing deal between Arvinas and Pfizer, worth an impressive $1bn if its equity element is included, highlighted again the resurgence of selective oestrogen degradation as an approach to treating ER-positive/Her2-negative breast cancer. And, though Pfizer is not the most advanced player, this was its third move into this space in recent years.